What does potency actually mean for inhaled corticosteroids?

Journal of Asthma

Volumn 42, Issue 6, 2005, Pages 409-417

  Williams, Dennis M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; MOMETASONE FUROATE; TIPREDANE; TRIAMCINOLONE ACETONIDE;

AIRWAY DYNAMICS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; IN VITRO STUDY; LIPOPHILICITY; META ANALYSIS; METERED DOSE INHALER; RECEPTOR AFFINITY; REVIEW; SKIN TEST; SYSTEMATIC REVIEW;

EID: 26944451258     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1081/JAS-200057878     Document Type: Review

References (88)

1. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148(4 part 2):S1-S26.
2. British Thoracic Society. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52(suppl. 1):S1-S21.
3. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma, National Asthma Education and Prevention Program. Expert Panel Report 2. NIH Publication 97-4051, Bethesda, MD: National Institutes of Health, 1997.
4. National Heart, Lung, and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH Publication 02-3659, Bethesda, MD: National Institutes of Health, 2002.
5. Williams DM. Clinical considerations in the use of inhaled corticosteroids for asthma. Pharmacotherapy 2001; 21(3 part 2):38S-48S.
6. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52(suppl 39):1-34.
7. National Heart, Lung, and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. WHO/NHLBI Workshop Report. NIH Publication 95-365, Bethesda, MD: National Institutes of Health, 1995.
8. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother 1998; 32(2):220-232.
9. Ståhl E. Correlation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studies. Respir Med 2001; 94(8):735-741.
10. DeNicola LR, Kissoon N, Duckworth LJ, Blake KV, Murphy SP, Silkoff PE. Exhaled nitric oxide as an indicator of severity of asthmatic inflammation. Pediatr Emerg Care 2000; 16(4):290-295.
11. Kharitonov SA, Barnes PJ. Clinical aspects of exhaled nitric oxide. Eur Respir J 2000; 16(4):781-792.
12. Payne DN. Nitric oxide in allergic airway inflammation. Curr Opin Allergy Clin Immunol 2003; 3(2):133-177.
13. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998; 101(4 part 2):S434-S439.
14. Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J 2003; 21(6):989-993.
15. O'Byrne PM, Pedersen S. Measuring efficacy and safety of different inhaled corticosteroid preparations. J Allergy Clin Immunol 1998; 102(6 part 1):879-886.
16. Jaffuel D, Demoly P, Gougat C, Balaguer P, Mautino G, Godard P, Bousquet J, Mathieu M. Transcriptional potencies of inhaled glucocorti-costeroids. Am J Respir Crit Care Med 2000; 162(1):57-63.
17. Kelly HW. Establishing a therapeutic index for the inhaled cortico-steroids. Part 1. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998; 102(4 part 2):S36-S51.
18. Brattsand R, Axelsson BI. New inhaled glucocorticosteroids. New Drugs Asthma 1992; 2:193-208.
19. Johansson S.Å, Andersson K.-E, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol 1982; 22(6):523-529.
20. Lutsky BN, Millonig RC, Wojnar RJ, Free CA, Devlin RG, Varma RK, Karanewsky DS. Androstene-17-thioketals. 2nd communication: pharmacological profiles of tipredane and (11β, 17α)-17-(ethylithio)-9α-fluoro- 17-[2-(fluoroethyl)thio] 11β-hydroxy-androsta-1,4-dien-3-one, structurally novel 20-thiasteroids possessing potent and selective topical anti-inflammatory activity. Arzneimittelforschung 1986; 36(12):1787-1795.
21. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84(suppl A):19-23.
22. Reed CE. Glucocorticoids in asthma. Immunol Allergy Clin North Am 1993; 13(4):903-915.
23. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962; 86:608-610.
24. Kharitonov SA, Rajakulasingam K, O'Connor B, Durham SR, Barnes PJ. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. J Allergy Clin Immunol 1997; 99(1 part 1):58-64.
25. Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Bames PJ. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002; 57(10):889-896.
26. Inman MD. The role of direct assessment of airway inflammation in evaluating inhaled glucocorticosteroid efficacy and in managing the asthmatic patient. In Inhaled Steroids in Asthma: optimizing effects in the airways. Schleimer RP, O'Byrne PM, Szefler SJ, Brattsand R, eds. New York: Marcel Dekker, Inc., 2002:421-439.
27. Green R, Brightling C, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360(9347):1715-1721.
28. Ashwell J, Lu F, Vacchio M. Glucocorticosteroids in T cell development and function. Annu Rev Immunol 2000; 18:309-345.
29. Place VA, Velaques JG, Burdick KH. Precise evaluation of topically applied corticosteroid potency. Arch Dermatol 1970; 101(5):531-537.
30. Andersson N, Klint S, Randwall G, Wirén J.-E. Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay. Am J Respir Crit Care Med 1994; 149(4 part 2):A467.
31. Randwall G, Klint S, Soderblom M, Larsson P, Andersson N, Lindgren S. Topical activity of glucocorticosteroids in the vasoconstriction assay: method comparison. Eur Respir J 1994; 7(suppl. 18):381S.
32. Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001; 23(9):1339-1354.
33. Lipworth BJ, Wilson AM. Dose response to inhaled corticosteroids: benefits and risks. Semin Respir Crit Care Med 1998; 19:625-646.
34. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Safety 2000; 23(1):11-33.
35. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157(3 part 2):S1-S53.
36. Bousquet J, Ben-Joseph R, Messonier M, Alemao E, Gould AL. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002; 24(1):1-20.
37. Boulet LP, Cockcroft DW, Toogood J, Lacasse Y, Baskerville J, Hargreave FE. Comparative assessment of safety and efficacy of inhaled corticosteroids: report of a committee of the Canadian thoracic society. Eur Respir J 1998; 11(5):1194-1210.
38. Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide turbuhaler and fluticasone propionate diskhaler. J Allergy Clin Immunol 1997; 99(6 part 1):773-780.
39. Kuna P, Joubert J, Greefhorst APM, Magnussen H. A randomized, double-blind, double-dummy, parallel-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone dry-powder inhalers in adults with mild to moderate asthma. Clin Ther 2003; 25(8):2182-2197.
40. Nielsen LP, Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma: a dose range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med 2000; 162(6):2053-2057.
41. Selroos O, Backman R, Forsén K.-O, Löfroos A.-B, Niemistö M, Pietinalho A, Riska H. Clinical efficacy of budesonide turbuhaler™ compared with that of beclomethasone dipropionate pmdi with volumatic spacer: a 2-year randomized study in 102 asthma patients. Allergy 1994; 49(10):833-836.
42. Brambilla C, Lacronique J, Allaert FA, Godard P, Duroux P, The French budesonide trial group. A 3-month comparative dose-reduction study with inhaled beclomethasone dipropionate and budesonide in the management of moderate to severe adult asthma. Drug Investig 1994; 8(1):49-56.
43. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, Colice GL. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104(6):1215-1222.
44. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69(1):130-133.
45. Beasley R, Sterk PJ, Kerstjens HA, Decramer M. Comparative studies of inhaled corticosteroids in asthma. Eur Respir J 2001; 17(4):579-580.
46. Reichel W, Dahl R, Ringdal N, Zetterström O, van den Elshout FJJ, Laitinen LA. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 μg/day) versus budesonide dry powder inhaler (800 μg/day) in asthma. Int J Clin Pract 2001; 55(2):100-106.
47. Worth H, Muir JF, Pieters WR. Comparison of hydrofluoroalkane- beclomethasone dipropionate autohaler™ with budesonide turbuhaler™ in asthma control. Respiration 2001; 68(5):517-526.
48. Pauwels RA, Yernault JC, Demedts MG, Geusens P. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Am J Respir Crit Care Med 1998; 157(3 part 1):827-832.
49. O'Connor B, Bonnaud G, Haahtela T, Luna JM, Querfurt H, Wegener T, Lutsky BN. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immun 2001; 86(4):397-404.
50. Chervinsky P, Nelson H, Bernstein D, Berkowitz R, Siegal S. Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate. Int J Clin Pract 2002; 56(6):419-425.
51. Bousquet J, D'Urzo A, Hebert J, Barraza CH, Boulet L.-P, Suárez-Chacón R, Harnest U, Lundbeck B, Martinez Morales G, Nieminen MN, Nolop KB, Visser S, Lutsky BN. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide turbuhaler®. Eur Respir J 2000; 16(5):808-816.
52. Adams N, Bestall JM, Lasserson TJ, Jones PW. Inhaled flucticasone versus inhaled belcomethasone or inhaled budesonide for chronic asthma. Cochrane Database Syst Rev 2004; 2:CD002310.
53. Thorsson L, Edsbäcker S, Källén A, Löfdahl C.-G. Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®. Br J Clin Pharmacol 2001; 52(5):529-538.
54. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159(9):941-955.
55. Thorsson L, Dahlström K, Edsbäcker S, Källén A, Paulson J, Wirén J.-E. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43(2):155-161.
56. Clark D, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51(3):262-266.
57. Donnelly R, Williams KM, Baker AB, Badcock CA, Day RO, Seale JP. Effects of budesonide and fluticasone on 24-hour plasma cortisol: a dose-response study. Am J Respir Crit Care Med 1997; 156(6):1746-1751.
58. Derom E, Van Schoor J, Verhaeghe W, Vincken W, Pauwels R. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med 1999; 160(1):157-161.
59. Committee on Safety of Medicines/Medicines Control Agency. Curr Probl Pharmacovigil 1998; 24:8.
60. Todd G, Acerini C, Ross-Russell R, Zahra S, Warner J, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87(6):457-461.
61. Committee on Safety of Medicines/Medicines Control Agency. Reminder: fluticasone propionate (flixotide): use of high doses (> 500 mg/twice daily). Curr Probl Pharmacovigil 2001; 27; 10.
62. British Thoracic Society. British guideline on the management of asthma. Thorax 2003; 58(suppl 1):1-97.
63. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (AAIA). The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immun 2000; 84(5):475-480.
64. Norjavaara E, Gerhardsson de Verdier M. Normal pregnancy outcomes in a population-based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003; 111(4):736-742.
65. Jadad AR, Sigouin C, Mohide PT, Levine M, Fuentes M. Risk of congenital malformations associated with treatment of asthma during pregnancy. Lancet 2000; 355(9198):119.
66. Kallen B, Rhydhstroem H, Aberg A. Asthma during pregnancy-a population based study. Eur J Epidemiol 2000; 16(2):167-171.
67. Silverman M, Sheffer A, Woolcock A, Diaz Amor P, Lindmark B, Radner F, Broddene M, Pedersen S, Pauwels R. Prospective Pregnancy Outcome Data in Patients With Recent Onset, Mild Persistent Asthma Treated With Once-Daily Budesonide: results from the START study. Presented at the American Thoracic Society, 2003, (A772).
68. Brutsche M, Brutsche I, Munawar W, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A, Woodcock A. Comparison of pharmacokinetics and systemic effects of inhaled flucticasone propionate in patients with asthma and healthy volunteers: a randomized study. Lancet 2000; 356(9229):556-561.
69. Fabbri L, Burge PS, Croonenborgh L, Warlies F, Weeke B, Ciaccia A, Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International study group. Thorax 1993; 48(8):817-823.
70. Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998; 92(1):95-104.
71. Edsbäcker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999; 58(suppl 4):7-16.
72. Affrime MB, Cuss F, Padhi D, Wirth M, Pai S, Clement RP, Lim J, Kantesaria B, Alton K, Cayen MN. Unavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000; 40(11):1227-1236.
73. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51(5):400-409.
74. Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone diskus and budesonide turbuhaler in children. Am J Respir Crit Care Med 2003; 168(7):779-782.
75. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, Cherniack RM, Craig TJ, Drazen JM, Fagen JK, Fahy JV, Fish JE, Ford JG, Israel E, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Peters SP, Sorkness CA. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165(10):1377-1383.
76. Mackie AE, McDowall JE, Falcoz C, Ventresca P, Bye A, Daley-Yates PT. Pharmacokinetics of fluticasone propionate inhaled via the diskhaler and diskus powder devices in healthy volunteers. Clin Pharmacokinet 2000; 39(suppl 1):23-30.
77. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7(10):1839-1844.
78. Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 2001; 14(suppl 1):S19-S26.
79. Colice GL. Comparing inhaled corticosteroids. Respir Care 2000; 45(7):846-853.
80. Miller-Larrson A, Jansson P, Runstrom A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000; 162(4 part 1):1455-1461.
81. Purucker ME, Rosebraugh CJ, Zhou F, Meyer RJ. Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 2003; 124(4):1584-1593.
82. Brattsand R. What factors determine anti-inflammatory activity and selectivity of inhaled steroids? Eur Respir Rev 1997; 7(50):356-361.
83. Brattsand R. Development of glucocorticosteroids with lung selectivity. In Glucocorticoids and Mechanisms of Asthma. Hargreaves FE, Hogg JC, Malo JL, Toogood JH, eds. Amsterdam: Excerpta Medica, 1989:17-38.
84. Edsbacker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue, review of available data. Ann Allergy Asthma Immun 2002; 88(6):609-616.
85. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide, novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26(7):623-630.
86. Tunek A, Sjodin K, Hallstrom G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997; 25(11):1311-1317.
87. Petersen H, Kullberg A, Edsbacker S, Greiff L. Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo. Br J Clin Pharmacol 2001; 51(2):159-163.
88. Thorsson L, Thunnisen FBJM, Korn S, Carlshaf A, Edsbäcker S, Wouters EFM. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo. Am J Respir Crit Care Med 1998; 157(suppl 3):A404.